Association of self-directed walking with toxicity moderation during chemotherapy for the treatment of early breast cancer.

dc.contributor.author

Nyrop, KA

dc.contributor.author

Page, A

dc.contributor.author

Deal, AM

dc.contributor.author

Wagoner, C

dc.contributor.author

Kelly, EA

dc.contributor.author

Kimmick, Gretchen G

dc.contributor.author

Copeland, Anureet

dc.contributor.author

Speca, JoEllen

dc.contributor.author

Wood, William A

dc.contributor.author

Muss, HB

dc.date.accessioned

2024-01-01T23:26:48Z

dc.date.available

2024-01-01T23:26:48Z

dc.date.issued

2023-12

dc.description.abstract

Background

In the field of exercise oncology, there is a need to quantify the potential benefits of moderate, self-directed physical activity during active treatment. In a pooled analysis of three identical single-arm intervention studies, we investigate the association of activity tracker steps with patient-reported toxicities during chemotherapy.

Methods

Women with early breast cancer who were enrolled in the intervention studies reported their symptom severity every 2-3 weeks throughout chemotherapy, and daily steps were documented through a Fitbit activity tracker. Relative risks (RR) and 95% confidence intervals (CI) were calculated using Poisson regression models with robust variance. For outcomes significant in unadjusted models, adjusted RRs were calculated controlling for race, age, and education level. Tracker step cut point (high step, low step) was determined by the means. Cumulative incidence functions of moderate, severe, and very severe (MSVS) symptoms were estimated using the Kaplan-Meier method and compared using a Cox proportional hazard model.

Results

In a sample of 283 women, mean age was 56 years and 76% were White. Mean tracker-documented steps/week were 29,625, with 55% walking below the mean (low step) and 45% above (high step). In multivariable analysis, high step patients had lower risk for fatigue [RR 0.83 (0.70, 0.99)] (p = 0.04), anxiety [RR 0.59 (0.42, 0.84)] (p = 0.003), nausea [RR 0.66 (0.46, 0.96)] (p = 0.03), depression [RR 0.59 (0.37, 0.03)] (p = 0.02), and ≥ 6 MSVS symptoms [RR 0.73 (0.54, 1.00)] (p = 0.05) and had 36% lower risk for dose reductions [RR 0.64 (95% CI 0.43, 0.97)] (p = 0.03).

Conclusion

Self-directed walking at a rate of at least 30,000 steps/week may moderate the severity of treatment side effects during chemotherapy for early breast cancer.

Trial numbers

NCT02167932, NCT02328313, NCT03761706.
dc.identifier

10.1007/s00520-023-08275-4

dc.identifier.issn

0941-4355

dc.identifier.issn

1433-7339

dc.identifier.uri

https://hdl.handle.net/10161/29601

dc.language

eng

dc.publisher

Springer Science and Business Media LLC

dc.relation.ispartof

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

dc.relation.isversionof

10.1007/s00520-023-08275-4

dc.rights.uri

https://creativecommons.org/licenses/by-nc/4.0

dc.subject

Humans

dc.subject

Breast Neoplasms

dc.subject

Exercise

dc.subject

Walking

dc.subject

Anxiety

dc.subject

Middle Aged

dc.subject

Female

dc.subject

Drug-Related Side Effects and Adverse Reactions

dc.title

Association of self-directed walking with toxicity moderation during chemotherapy for the treatment of early breast cancer.

dc.type

Journal article

pubs.begin-page

68

pubs.issue

1

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Medicine

pubs.organisational-group

Medicine, Medical Oncology

pubs.organisational-group

Duke Cancer Institute

pubs.publication-status

Published

pubs.volume

32

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
SuppCareCancer Nyrop2024_selfdirected walking&tox in EBC.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format